Zai Lab Ltd. Unsponsored ADR Stock

$26.72

1.91% yesterday

Nasdaq, Dec 20, 10:00 pm CET

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Zai Lab Ltd. Unsponsored ADR Stock price

$26.72

-12.28 31.49% 5Y

Nasdaq, Closing price Fri, Dec 20 2024

+0.50 1.91%

ISIN

US98887Q1040

Symbol

ZLAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$2.91b
Enterprise Value	$2.32b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	6.52
P/S ratio (TTM) P/S ratio	8.18
P/B ratio (TTM) P/B ratio	3.94
Revenue growth (TTM) Revenue growth	35.01%
Revenue (TTM) Revenue	$355.75m
EBIT (operating result TTM) EBIT	$-338.21m
Free Cash Flow (TTM) Free Cash Flow	$-178.00m
Cash position	$716.09m
EPS (TTM) EPS	$-2.78
P/E forward	negative
P/S forward	7.40
EV/Sales forward	5.90
Short interest	5.48%

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Get Started for Free Today

Zai Lab Ltd. Unsponsored ADR Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

9x Buy

82%

2x Hold

18%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

Buy

82%

Hold

18%

Analyst Estimates with Stock Price Targets

Financial data from Zai Lab Ltd. Unsponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	356 356	35% 35% 100%
- Direct Costs	131 131	43% 43% 37%
Gross Profit	225 225	31% 31% 63%
- Selling and Administrative Expenses	279 279	10% 10% 79%
- Research and Development Expense	264 264	5% 5% 74%
EBITDA	-319 -319	4% 4% -90%
- Depreciation and Amortization	19 19	9% 9% 5%
EBIT (Operating Income) EBIT	-338 -338	3% 3% -95%
Net Profit	-271 -271	10% 10% -76%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Zai Lab Ltd. Unsponsored ADR Stock News

Neutral

Business Wire

●

9 days ago

Zai Lab Announces Participation in Investor Conference in January 2025

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conference in January 2025: 43rd Annual J.P. Morgan Healthcare Conference Presentation: Tuesday, January 14, 2025, 1:30 p.m. PST Location: San Francisco A live webcast of the presentation will be ...

Neutral

Business Wire

●

19 days ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

SHANGHAI & CAMBRIDGE, Mass. & ROOT, Switzerland--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Novocure (NASDAQ: NVCR) announced today that the pivotal, Phase 3 PANOVA-3 trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) versus control. PANOVA-3 evaluated the use of Tumor Treating Fields (TTFields) therapy con...

Neutral

Business Wire

●

23 days ago

Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications: AUGTYRO® (repotrectinib) is included in the NRDL for the treatment of adult patients with locally ...

More Zai Lab Ltd. Unsponsored ADR News

Company Profile

Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.

Head office	Cayman Islands
CEO	Ying Du
Employees	2,175
Founded	2014
Website	www.zailaboratory.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now